BCL6 Is Required for Differentiation of Ig-Like Transcript 3-Fc-Induced CD8+ T Suppressor Cells

被引:25
作者
Chang, Chih-Chao [1 ]
Vlad, George [1 ]
D'Agati, Vivette D. [1 ]
Liu, Zhuoru [1 ]
Zhang, Qing-yin [2 ]
Witkowski, Piotr [3 ]
Torkamani, Ali A. [4 ]
Stokes, Michael B. [1 ]
Ho, Eric K. [1 ]
Cortesini, Raffaello [1 ]
Suciu-Foca, Nicole [1 ]
机构
[1] Columbia Univ, Dept Pathol & Cell Biol, New York, NY 10032 USA
[2] Columbia Univ, Dept Surg, New York, NY 10032 USA
[3] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
[4] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
关键词
INHIBITORY RECEPTOR ILT3; DENDRITIC CELLS; SIGNALING PATHWAY; EXPRESSION; INDUCTION; RESPONSES; PLASTICITY;
D O I
10.4049/jimmunol.1001732
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ig-like transcript 3 (ILT3) is an inhibitory receptor expressed by tolerogenic dendritic cells. When human CD8(+) T cells are allostimulated in the presence of recombinant ILT3-Fc protein, they differentiate into antigenic specific T suppressor (Ts) cells that inhibit CD4 and CD8 T cell effector function both in vitro and in vivo. ILT3-Fc-induced CD8(+) Ts cells express high amounts of BCL6 that are crucial to their function. Knockdown of BCL6 from unprimed human T cells prevents their differentiation into Ts cells, whereas ex vivo overexpression of BCL6 converts CD8(+) T cells into Ts cells. NOD/SCID mice transplanted with human pancreatic islets and humanized by injection of human PBMCs tolerate the graft and develop BCL6(high) CD8(+) Ts cells when treated with ILT3-Fc before or after the onset of rejection. This indicates that ILT3-Fc acts through BCL6 and is a potent immunosuppressive agent for reversing the onset of allo-or possibly autoimmune attacks against pancreatic islets. The Journal of Immunology, 2010, 185: 5714-5722.
引用
收藏
页码:5714 / 5722
页数:9
相关论文
共 42 条
[1]   The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes [J].
Aboumrad, E. ;
Madec, A. M. ;
Thivolet, C. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2007, 148 (03) :432-439
[2]   Pharmacological induction of tolerogenic dendritic cells and regulatory T cells [J].
Adorini, L ;
Giarratana, N ;
Penna, G .
SEMINARS IN IMMUNOLOGY, 2004, 16 (02) :127-134
[3]  
Adorini Luciano, 2009, Handb Exp Pharmacol, P251, DOI 10.1007/978-3-540-71029-5_12
[4]   Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists [J].
Adorini, Luciano ;
Penna, Giuseppe .
HUMAN IMMUNOLOGY, 2009, 70 (05) :345-352
[5]   A putative silencer element in the IL-5 gene recognized by Bcl6 [J].
Arima, M ;
Toyama, H ;
Ichii, H ;
Kojima, S ;
Okada, S ;
Hatano, M ;
Cheng, G ;
Kubo, M ;
Fukuda, T ;
Tokuhisa, T .
JOURNAL OF IMMUNOLOGY, 2002, 169 (02) :829-836
[6]   The functional plasticity of T cell subsets [J].
Bluestone, Jeffrey A. ;
Mackay, Charles R. ;
O'Shea, John J. ;
Stockinger, Brigitta .
NATURE REVIEWS IMMUNOLOGY, 2009, 9 (11) :811-816
[7]   The LILR family: modulators of innate and adaptive immune pathways in health and disease [J].
Brown, D ;
Trowsdale, J ;
Allen, R .
TISSUE ANTIGENS, 2004, 64 (03) :215-225
[8]   A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing [J].
Cella, M ;
Dohring, C ;
Samaridis, J ;
Dessing, M ;
Brockhaus, M ;
Lanzavecchia, A ;
Colonna, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (10) :1743-1751
[9]   Tolerization of dendritic cells by TS cells:: the crucial role of inhibitory receptors ILT3 and ILT4 [J].
Chang, CC ;
Ciubotariu, R ;
Manavalan, JS ;
Yuan, J ;
Colovai, AI ;
Piazza, F ;
Lederman, S ;
Colonna, M ;
Cortesini, R ;
Dalla-Favera, R ;
Suciu-Foca, N .
NATURE IMMUNOLOGY, 2002, 3 (03) :237-243
[10]   BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor [J].
Chang, CC ;
Ye, BH ;
Chaganti, RSK ;
DallaFavera, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (14) :6947-6952